RE:RE:RE:RE:Market cap
"Amazing" ? Look at the Y/Y R&D expenditures, there had to be some actual progress to report.
I'm happy just to not get any bad news about remaining burn time or milestone dates. Maybe I should call that amazing, but what a low bar.
Is it a very sellable story in a bear market? And is that the job of a CFO? Or are you just agreeing that the CEO is deadwood? I don't want to see more exec compensation added before early P1 results. I don't want to be betting that the next headhunting effort finally results in closing the first pharma deal during a bear market with the big pharma players enjoying more leverage than at any time in history.
But I'd like to hear a good argument for how a competent CFO could make a make a difference in our prospects with a Nasdaq listing, so what are you thinking?